Twist Bioscience Corporation (NASDAQ:TWST) is one of the 10 Best Performing American Stocks in June 2026.
On July 6, 2026, Evercore ISI downgraded Twist Bioscience Corporation (NASDAQ:TWST) to In Line from Outperform with a price target of $102, up from $66. Evercore ISI said Twist has been one of the best performers in life science tools, up more than 200% year-to-date, with most of the move, or 85%, coming since its May 21 ***** yst day on optimism around AI-driven order momentum. The firm said it is taking some profits after the rally.
On June 29, Guggenheim raised the firm's price target on Twist Bioscience to $107 from $60 and kept a Buy rating on the shares. Guggenheim adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.
Pixabay/Public Domain
On June 24, Barclays ***** yst Luke Sergott raised the firm's price target on Twist Bioscience to $95 from $65 and kept an Overweight rating on the shares. Sergott adjusted targets in the life science and diagnostic tools ***** e as part of a Q2 preview, noting that tools are "gaining favor among healthcare subsectors." Barclays expects in-line to modest beats in Q2 for the group.
On July 6, 2026, Evercore ISI downgraded Twist Bioscience Corporation (NASDAQ:TWST) to In Line from Outperform with a price target of $102, up from $66. Evercore ISI said Twist has been one of the best performers in life science tools, up more than 200% year-to-date, with most of the move, or 85%, coming since its May 21 ***** yst day on optimism around AI-driven order momentum. The firm said it is taking some profits after the rally.
On June 29, Guggenheim raised the firm's price target on Twist Bioscience to $107 from $60 and kept a Buy rating on the shares. Guggenheim adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.
Pixabay/Public Domain
On June 24, Barclays ***** yst Luke Sergott raised the firm's price target on Twist Bioscience to $95 from $65 and kept an Overweight rating on the shares. Sergott adjusted targets in the life science and diagnostic tools ***** e as part of a Q2 preview, noting that tools are "gaining favor among healthcare subsectors." Barclays expects in-line to modest beats in Q2 for the group.
23 days ago
